参考文献/References:
[1]Farnierm M. PCSK9:from discovery to therapeutic applications [J]. Arch Cardiovasc Dis,2014,107(1):58-66.
[2]Warden BA,Fazio S,Shapiro MD,et al. The PCSK9 revolution:current status,controversies,and future directions[J]. Trends Cardiovasc Med,2020,30(3):179-185.
[3]杜函洋,徐玢,杨铁城,等. 急性冠脉综合征患者前蛋白转化酶枯草溶菌素9水平及临床意义[J]. 中国临床医生杂志,2019,47(7):786-788.
[4]Durairaj A,Sabates A,Nieves J,et al. Proprotein convertase subtilisin/kexin type 9(PCSK9) and its inhibitors:a review of physiology,biology,and clinical data[J]. Curr Treat Options Cardiovasc Med,2017,19(8):58.
[5]Bandyopadhyay D,Ashish K,Hajra A,et al. Cardiovascular outcomes of PCSK9 inhibitors:with special emphasis on its effect beyond LDL-cholesterol lowering[J]. J lipids,2018,2018:3179201.
[6]Ding ZF,Liu SJ,Wang XW,et al. Cross-talk between LOX-1 and PCSK9 in vascular tissues[J]. Cardiovasc Res,2015,107(4):556-567.
[7]Chaudhary R,Garg J,Shah N,et al. PCSK9 inhibitors:a new e ra of lipid lowering therapy[J]. World J Cardiol,2017,9(2):76-91.
[8]Schwartz GG,Steg PG,Szarek M,et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome[J]. N Engl J Med,2018,379(22):2097-2107.
[9]Jukema JW,Szarek M,Zijlstra LE,et al. Alirocumab in patients with polyvascular disease and recent acute coronary syndrome:ODYSSEY OUTCOMES trial[J]. J Am Coll Cardiol,2019,74(9):1167-1176.
[10]Damask A,Steg PG,Schwartz GG,et al. Patients with high genome-wide polygenic risk scores for coronary artery disease may receive greater clinical benefit from alirocumab treatment in the ODYSSEY OUTCOMES Trial[J]. Circulation ,2020,141(8):624-636.
[11]Colhoun HM,Leiter LA,Mullerwieland D,et al. Effect of alirocumab on individuals with type 2 diabetes,high triglycerides,and low high-density lipoprotein cholesterol[J]. Cardiovasc Diabetol,2020,19(1):14.
[12]Toth PP,Dwyer JP,Cannon CP,et al. Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease[J]. Kidney Int,2018,93(6):1397-1408.
[13]Ferri N,Grego MF,Corsini A,et al. Proprotein convertase subtilisin/kexin type 9:an update on the cardiovascular outcome studies[J]. Eur Heart J Suppl,2020,22(suppl E):E64-E67.
[14]Sabatine MS,Leiter LA,Wiviott SD,et al. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes:a prespecified analysis of the FOURIER randomised controlled trial[J]. Lancet Diabetes Endocrinol,2017,5(12):941-950.
[15]Sabatine MS,de Ferrari GM,Giugliano RP,et al. Clinical benefit of evolocumab by severity and extent of coronary artery disease:analysis from FOURIER[J]. Circulation,2018,138(8):756-766.
[16]Bonaca MP,Nault P,Giugliano RP,et al. Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease:insights from the FOURIER trial(Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)[J]. Circulation,2018,137(4):338-350.
[17]Sabatine MS,Giugliano RP,Keech AC,et al. Evolocumab and clinical outcomes in patients with cardiovascular disease[J]. N Engl J Med,2017,376(18):1713-1722.
[18]Marston N,Kamanu FK,Nordio F,et al. Predicting benefit from evolocumab therapy in patients with atherosclerotic disease using a genetic risk score:results from the FOURIER trial[J]. Circulation,2020,141(8):616-623.
[19]Santos RD,Stein EA,Hovingh GK,et al. Long-term evolocumab in patients with familial hypercholesterolemia[J]. J Am Coll Cardiol,2020,75(6):565-574.
[20]Blom DJ,Hala T,Bolognese M,et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia[J]. N Engl J Med,2014,370(19):1809-1819.
[21]Khoury E,Brisson D,Gaudet D,et al. Preclinical discovery and development of evolocumab for the treatment of hypercholesterolemia[J]. Expert Opin Drug Discov,2020,15(4):403-414.
[22]Raal FJ,Honarpour N,Blom DJ,et al. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia(TESLA Part):a randomized,double-blind,placebo-controlled trial[J]. Lancet,2015,385(9965):341-350.
[23]Sabatine MS,Giugliano RP,Wiviott SD,et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events[J]. N Engl J Med ,2015,372(16):1500-1509.
[24]Lorenzatti AJ,Eliaschewitz FG,Chen Y,et al. Randomised study of evolocumab in patients with type 2 diabetes and dyslipidaemia on background statin:primary results of the BERSON clinical trial[J]. Diabetes Obes Metab,2019,21(6):1455-1463.
[25]Guedeney P,Sorrentino S,Giustino G,et al. Indirect comparison of the efficacy and safety of alirocumab and evolocumab:a systematic review and network meta-analysis[J]. Eur Heart J Cardiovasc Pharmacother,2021,7(3):225-235.
[26]Siasos G,Oikonomou E,Tousoulis D. Alirocumab and evolocumab:an indirect comparison of cardiovascular benefits[J]. Eur Heart J Cardiovasc Pharmacother,2021,7(3):236-237.
[27]Rosenson RS,Hegele RA,Fazio S,et al. The evolving future of PCSK9 inhibitors[J]. J Am Coll Cardiol,2018,72(3):314-329.
[28]Warden BA,Fazio S,Shapiro MD,et al. The PCSK9 revolution:current status,controversies,and future directions[J]. Trends Cardiovasc Med,2020,30(3):179-185.
[29]Ray KK,Landmesser U,Leiter LA,et a l. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol[J]. N Engl J Med,2017,376(15):1430-1440．
[30]Wright RS,Collins MG,Stoekenbroek RM,et al. Effects of renal impairment on the pharmacokinetics,efficacy,and safety of inclisiran:an analysis of the ORION-7 and ORION-1 studies[J]. Mayo Clin Proc,2020,95(1):77-89.
[31]Sehgal A,Vaishnaw A,Fitzgerald K. Liver as a target for oligonucleotide therapeutics[J]. J Hepatol,2013,59(6):1354-1359.
[32] Graham MJ,Lemonidis KM,Whipple CP,et al. Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice[J]. J Lipid Res,2007,48(4):763-767.
[33]Lindholm MW,Elmen J,Fisker N,et al. PCSK9 LNA antisense oligonucleotides induce sustained reduction of LDL cholesterol in nonhuman primates[J]. Mol Ther,2012,20(2):376-381.
[34]中国成人血脂异常防治指南修订联合委员会. 中国成人血脂异常防治指南（2016年修订版）[J]. 中华全科医师杂志,2017,16(1):15-35.
[35]Orringer CE,Jacobson TA,Saseen JJ,et al. Update on the use of PCSK9 inhibitors in adults:Recommendations from an Expert Panel of the National Lipid Association[J]. J Clin Lipidol,2017,11(4): 880-890.
[36]Mach F,Baigent C,Catapano AL,et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias:lipid modification to reduce cardiovascular risk[J]. Eur Heart J,2020,41(1):111-188.
相似文献/References:
[1]胥雪莲,何川.前蛋白转化酶枯草溶菌素9与动脉粥样硬化[J].心血管病学进展,2016,(1):50.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.013]
XU Xuelian,HE Chuan.Proprotein Convertase Subtilisin/Kexin Type 9 and Atherosclerosis[J].Advances in Cardiovascular Diseases,2016,(9):50.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.013]
[2]乐健 何胜虎.前蛋白转化酶枯草溶菌素9致动脉粥样硬化的机制研究进展[J].心血管病学进展,2019,(7):1000.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.009]
YUE Jian,HE Shenghu.Advances in the mechanism of PCSK9-induced atherosclerosis[J].Advances in Cardiovascular Diseases,2019,(9):1000.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.009]
[3]孟凡华 付真彦.一种新型的治疗血脂异常的干扰RNA药物Inclisiran[J].心血管病学进展,2021,(2):167.[doi:10.16806/j.cnki.issn.1004-3934.2021.02.018]
MENG Fanhua,FU Zhenyan.Inclisiran, A New Small Interfering RNA Drug for the Treatment of Dyslipidemia[J].Advances in Cardiovascular Diseases,2021,(9):167.[doi:10.16806/j.cnki.issn.1004-3934.2021.02.018]
[4]刘力黎 陈诚 张丽敏.血脂水平与心房颤动相关性研究进展[J].心血管病学进展,2021,(6):539.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.015]
LIU Lili,CHEN Cheng,ZHANG Limin.Serum Lipid Level and Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2021,(9):539.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.015]
[5]袁荣辉 白春林.贝派地酸降脂疗效及安全性的研究进展[J].心血管病学进展,2021,(9):809.[doi:10.16806/j.cnki.issn.1004-3934.2021.09.000]
(.Shanxi Medical University,Taiyuan 0000,Shanxi,et al.YUAN Ronghui1,BAI Chunlin2[J].Advances in Cardiovascular Diseases,2021,(9):809.[doi:10.16806/j.cnki.issn.1004-3934.2021.09.000]
[6]肖明瑛 苏冠华.PCSK9抑制剂多效性研究进展[J].心血管病学进展,2022,(2):124.[doi:10.16806/j.cnki.issn.1004-3934.2022.02.008]
XIAO MingyingSU Guanhua.Pleiotropic Effects of PCSK9 Inhibitors[J].Advances in Cardiovascular Diseases,2022,(9):124.[doi:10.16806/j.cnki.issn.1004-3934.2022.02.008]
[7]王兰 叶玉兰 宁明安 张迪 尚粉青.血清PCSK9水平与PCI后冠状动脉病变再进展的关系研究[J].心血管病学进展,2022,(7):667.[doi:10.16806/j.cnki.issn.1004-3934.2022.07.000]
WANG Lan,YE Yulan,NING Mingan,et al.Correlation Analysis Between Serum PCSK9 Level and Coronary Artery Pathological ?Progression After PCI[J].Advances in Cardiovascular Diseases,2022,(9):667.[doi:10.16806/j.cnki.issn.1004-3934.2022.07.000]
[8]许晓宇 唐炯 郑甲林.PCSK9对血管内皮功能影响的研究进展[J].心血管病学进展,2023,(6):551.[doi:10.16806/j.cnki.issn.1004-3934.2023.06.016]
XU Xiaoyu,TANG Jiong,ZHENG Jialin.Research Progress on the Effects of PCSK9 on Vascular Endothelial Function[J].Advances in Cardiovascular Diseases,2023,(9):551.[doi:10.16806/j.cnki.issn.1004-3934.2023.06.016]
[9]黄橙 李波 李志勇 陈紫君.过低LDL-C在动脉粥样硬化性心血管疾病中潜在风险循证学证据[J].心血管病学进展,2023,(11):1041.[doi:10.16806/j.cnki.issn.1004-3934.2023.11.019]
Huang Cheng,Li Bo,Li Zhiyong,et al.The Evidence of the Potential Risk of Excessively Low Levels of LDL-C in ASCVD[J].Advances in Cardiovascular Diseases,2023,(9):1041.[doi:10.16806/j.cnki.issn.1004-3934.2023.11.019]
[10]李开炜 彭汶婷 祝烨.降脂药物与认知功能下降的研究进展[J].心血管病学进展,2024,(3):220.[doi:10.16806/j.cnki.issn.1004-3934.2024.03.007]
LI Kaiwei,PENG Wenting,ZHU Ye.Lipid-Lowering Drugs and Cognitive Function Decline[J].Advances in Cardiovascular Diseases,2024,(9):220.[doi:10.16806/j.cnki.issn.1004-3934.2024.03.007]
[11]李艳茹,白世茹,李如意,等.PCSK9抑制剂在血脂代谢中的研究进展[J].心血管病学进展,2020,(7):729.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.014]
LI Yanru,BAI Shiru,LI Ruyi,et al.PCSK9 Inhibitors in Lipid Metabolism[J].Advances in Cardiovascular Diseases,2020,(9):729.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.014]
[12]王申仪 阳军.基于RNA疗法在动脉粥样硬化性心血管疾病血脂管理的研究进展[J].心血管病学进展,2021,(4):369.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.019]
Wang Shenyi,Yang Jun.Era of RNA-based Therapies in Lipid Management of?oronary Atherosclerotic Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2021,(9):369.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.019]
[13]许海南 龙明智.新型降脂药物干扰小RNA Inclisiran最新研究进展[J].心血管病学进展,2021,(7):590.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.004]
XU Hainan,LONG Mingzhi.Small Interfering RNA Inclisiran[J].Advances in Cardiovascular Diseases,2021,(9):590.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.004]
[14]乔斌超 贾永平.小干扰RNA降脂药物英克司兰研究进展[J].心血管病学进展,2024,(6):525.[doi:10.16806/j.cnki.issn.1004-3934.2024.06.011]
QIAO Binchao,JIA Yongping.Small Interfering RNA Lipid-Lowering Drug of Inclisiran[J].Advances in Cardiovascular Diseases,2024,(9):525.[doi:10.16806/j.cnki.issn.1004-3934.2024.06.011]